The Antihelminthic Drug, Mebendazole, Induces Apoptosis in Adult T-cell Leukemia/Lymphoma Cancer Cells: In-vitro Trial
Background: Adult T-cell leukemia/lymphoma (ATLL) is a poor prognostic Hematopoietic malignancy with various therapeutic challenges, which had been classified as non-Hodgkin lymphoma. The Drug switching, as a novel, innovative and promising approach, is an opportunity to overcoming on therapeutic challenges of hard-treating disease, e.g. ATLL. Our aim is evaluating the antiproliferative and apoptotic effect of Mebendazole (MBZ) on ATLL cancer cells in in-vitro conditions.
Materials and Methods: We used Jurkat cell-line as ATLL cancer cells. After treatment of MBZ in different concentrations on jurkat cells, the cell viabilities were determined by MTT assay. After IC50 value determination, the 24-, 48- and 72-h treatments had been performed in IC50 concentration and control to evaluating the quantitative apoptosis rate by Annexin/PI Flowcytometry and qualitative apoptosis by DAPI Nuclear staining. Also, Glucose spectrophotometry were performed to evaluate the reduced amount of glucose uptake through MBZ treatment.
Results: MBZ inhibits proliferation of jurkat cells and IC50 value had been estimated 10 μM (P< 0.01). According to the flowcytometric results, increasing in drug concentration is associated with decrease cell viability and the percentage of full-apoptosis. However, it inversely correlates with percentage of early-apoptosis rate. Also, the microscopic captures of DAPI Nuclear staining confirms the flowcytometry results in qualitative manner. In addition, it was found that inhibition of glucose uptake was inversely correlated with increased MBZ concentration (P< 0.05).
Conclusion: MBZ potentially inhibits the proliferation of ATLL cancer cells in in-vitro condition. MBZ inhibits the growth of Jurkat cells by inducing apoptosis. Also, we suggest that indirectly inhibition of Glucose transporting occurs by MBZ, which could induce apoptosis in cancer cells.
2. Bertazzoni U, Ciminale V, Romanelli MG. Editorial: Molecular Pathology of HTLV-1. Front Microbiol. 2018; 9: 3069.
3. Ratner L, Rauch D, Abel H, , et al. Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma. Blood Cancer J. 2016;6:e408.
4. Herrera DAA, Vishnuvardhan N, Butler M, et al. Barriers and Outcomes of Allogeneic Stem Cell Transplant (AlloSCT) for Human T Cell Lymphotropic Virus 1 (HTLV-1) Associated Adult T-Cell Lymphoma-Leukemia (ATLL) in the United States (US) from a Large Cohort in a Major Tertiary Center. Biol Blood Marrow Transplant . 2019;25(6):e199-e203.
5. Maali A, Atashi A, Ghaffari S, et al. A Review on Leukemia and iPSC Technology: Application in Novel Treatment and Future. Curr Stem Cell Res Ther. 2018;13(8):665-75.
6. Hermine O, Ramos JC, Tobinai K. A Review of New Findings in Adult T-cell Leukemia-Lymphoma: A Focus on Current and Emerging Treatment Strategies. Adv Ther. 2018;35(2):135-52.
7. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27(3):453-9.
8. Amiri S, Atashi A, Azad M, et al. Upregulation of Pro-inflammatory Cytokine Genes by Parvovirus B19 in Human Bone Marrow Mesenchymal Stem Cells. Biochem Genet. 2019; 58(1):63-73.
9. Allarakhia M. Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases. Drug Des Devel Ther. 2013; 7: 753–766.
10. Maali A, Ferdosi-Shahandashti E, Azad M. Drug Switching, a Creative Approach to Leukemia Therapy. IJBC. 2019;11(3):111-112.
11. Kohler P. The biochemical basis of anthelmintic action and resistance. Int J Parasitol. 2001;31(4):336-45.
12. Skibinski CG, Williamson T, Riggins GJJJon-o. Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma. J Neurooncol. 2018; 140(3): 529–538.
13. Sasaki J, Ramesh R, Chada S, et al. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther. 2002;1(13):1201-9.
14. Bai RY, Staedtke V, Aprhys CM, et al. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol. 2011;13(9):974-82.
15. Nygren P, Fryknas M, Agerup B, et al. Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. J Cancer Res Clin Oncol. 2013;139(12):2133-40.
16. Doudican NA, Byron SA, Pollock PM, et al. XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. Anticancer Drugs. 2013;24(2):181-8.
17. Dobrosotskaya IY, Hammer GD, Schteingart DE, et al. Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma. Endocr Pract. 2011;17(3):e59-62.
18. Hanusova V, Skalova L, Kralova V, et al. Potential anti-cancer drugs commonly used for other indications. Curr Cancer Drug Targets. 2015;15(1):35-52.
19. Bai R-Y, Staedtke V, Aprhys CM, Gallia GL, et al. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol. 2011; 13(9): 974–982.
|Issue||Vol 14, No 4 (2020)|
|Adult T-cell leukemia/lymphoma, Mebendazole, Drug switching, Apoptosis|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|